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Inhibition of marrow thymidine incorporation from sera of pa-
tients with uremia. A low-molecular-weight fraction of serum
samples from 14 patients with uremia inhibited tritiated thymi-
dine incorporation (18 2%) by cultured rabbit marrow whereas
an identical fraction from nonazotemic subjects did not. A simi-
lar effect on ferrous 59 incorporation into heme was observed. A
significantly smaller inhibition (8 2%) was noted in serum sam-
ples from patients on maintenance dialysis. The fraction contain-
ing inhibitory activity was filterable through a membrane that
had a nominal mol-wt cutoff of 10,000 daltons (Amicon® UM-lO)
and was retained wholly or in part on a membrane that had a 500-
dalton cutoff (UM-05). On Sephadex® G-50 and G-15 filtration,
the inhibitory substance appeared in the first absorbance peak.
This substance from 2 patients maintained on dialysis was stud-
ied further for its inhibitory activity. Dose-responsiveness was
noted. The inhibitor was stable when it was heated to 56° C for 60
mm, but the activity was lost immediately when it was heated to
100° C. Significant inactivation was observed following in-
cubation with protease and papain. The inhibitor was partially
soluble in chloroform. Taken together, these data suggest that
uremic serum contains an inhibitor of marrow DNA synthesis in
vitro, which may consist of peptides with mol wt less than 10,000
daltons and probably greater than 1,000 daltons. PTH or a mix-
ture of urea, creatinine, methylguanidine, and guanidosuccinic
acid did not show such inhibition on the marrow. This in vitro
system offers a simple and reproducible method of testing van-
ous fractions of serum to allow further characterization of some
toxic materials in uremic serum.
Presence, dans le serum de malades uremiques, d'un inhibiteur
de I'incorporation de Ia thymidine. Une fraction sérique de
faible poids moléculaire obtenue de 14 malades urémiques deter-
mine une inhibition de 18 2% de l'incorporation de thymidine
3H par la moelle osseuse de lapin en culture. Un effet semblable
sur I'incorporation du ferrous 59 dans l'hème a été observe. Les
deux effets peuvent être en rapport avec un retard de pro-
lifCration des cellules mCdullaires in vitro et n'ont pas été ob-
serves quand le tissu a été cultivé avec des fractions seriques
provenant de sujets non azotCmiques. L'inhibition déterminée
par le serum de malades en dialyse existe (8 2%) mais die est
significativement inférieure. La fraction qui contient l'activité in-
hibitrice est ultrafiltrable a travers une membrane dont le point
de coupure théorique est de 100 000 daltons (Amicon® UM-lO),
elle est retenue, complCtement ou en partie, par une membrane
dont Ic point de coupure est de 500 daltons (UM-05). En chro-
matographie sur Sephadex® G-25 ou G-15 cette fraction apparait
tardivement et conserve la plus grande partie de son activité mi-
tiale. La fraction obtenue chez deux malades en hémodialyse a
fait l'objet d'une étude plus poussée. Une relation dose-réponse
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a été observée. Bien qu'elle ne soit pas altérée par Ic chauffage a
56° C pendant 60 mm, elle est rapidement inactivée a 100° C.
L'incubation avec de Ia protéase et de la papaine l'inactive part-
iellement. Elle est soluble, au moms en partie, dans Ic chloro-
forme. Des concentrations dCcelables de substance de type pep-
tidique ont été mesurées dans Ia fraction soluble dans le chioro-
forme. L'ensemble de ces résultats suggére que le serum
urémique contient un peptide de faible poids moléculaire (ap-
proximativement 2500 a 10 000 daltons) qui inhibe Ia pro-
lifération de Ia moelle osseuse in vitro. La culture de ces mêmes
cellules mCdullaires avec chacune des deux formes d'hormone
parathyroidienne, avec d l'urée, de Ia créatinine, Ia methylguani-
dine ou l'acide guanidosuccinique ne determine pas d'inhibition.
Cette étude, pas plus que les precedentes, ne démontre une rela-
tion significative entre l'inhibition in vitro et l'urémie clinique.
Ce système in vitro, cependant, offre une méthode simple et re-
productible pour évaluer différentes fractions seriques afin de
mieux caractériser certains constituants toxiques dans Ic serum
de l'homme uremique.
The characterization of dialyzable, presumably
toxic, substances in the blood of patients with ure-
mia remains an elusive task. The clinical response
of these patients to deliberate variations of mainte-
nance hemodialysis techniques suggests that toxic
substances in the mol-wt range of 1000 to to 5000 dal-
tons are present in their serum [1]. Also, UV-light-
monitored gel-filtration chromatography of serum
samples reveals absorbance peaks in this molecular-
weight range; these peaks are not found or are pres-
ent in much smaller amounts in chromatographed
normal serum [2]. These peaks, however, probably
contain a heterogeneous group of substances, some
of which may not be toxic. Further separation and
characterization of the toxic components, impor-
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tant in the study of uremia, require the development
of in vitro toxicity tests. These tests have been at-
tempted against the growth of fibroblasts [3], mito-
gen-stimulated lymphocytes [4], and hepatic cells
[5]. An adverse or toxic effect of uremic serum for
the cultured bone marrow has been demonstrated in
the past, but the utilization of this model to study
the toxins has not been well explored [6-13]. One
important exception is the study of Wallner and
Vautrin, in which inhibition of ferrous 59 incorpora-
tion by cultured dog marrow was demonstrated in
whole uremic serum and its chloroform-soluble
fraction [14].
We report the results of similar efforts, which dif-
fer in several respects from previous studies. (1) We
tested portions of fractionated and chromato-
graphed serum in a marrow culture system and
found ultrafilterable inhibitory substances to be
principally in a mol-wt fraction between 1000 and
10,000 daltons. (2) Although inhibition of heme syn-
thesis is also demonstrable in our system, we relied
on a simpler method using tritiated thymidine incor-
poration throughout most of the studies. We also
tested the sensitivity of the inhibitory substance(s)
to three different proteolytic enzymes [4]. Finally,
we used this in vitro model to determine thermo-
lability and chloroform solubility of the inhibitor for
comparison with the previous work of Wallner and
Vautrin, and to test the effect of urea, creatinine,
methylguanidine, guanidosuccinic acid, and PTH.
Methods
Human subjects. Studies were carried out with
the serum samples of 22 patients (21 men and 1
woman) and 9 male employees of the Durham Vet-
erans Administration Medical Center. Participants
gave informed consent, and the study protocols
were approved by the Medical Center Human
Study Committee. Three clinically distinct patient
groups were studied. Group A consisted of 14 pa-
tients (ages 27 to 60 years; average age, 46 years)
with end-stage renal disease whose creatinine clear-
ances were less than 3 ml/min. Each required the
institution of maintenance dialysis because of the
presence of uremia symptoms. Blood samples were
collected just before the first dialysis. Group B con-
sisted of 14 patients (ages 27 to 70 years; average
age, 50 years), 6 of whom were also group A pa-
tients at an earlier time, who had been treated with
maintenance dialysis three times per week, 4 hours
per treatment, for between 1 and 51 months (average
time, 25 months). Each of the group B patients was
ambulatory and appeared to be in a similar state of
general health. The hematocrit range of group A
was 17 to 27% (average hematocrit, 23%), and that
of group B was 18 to 36% (average, 24%). Blood
samples for testing group B patients were drawn 1
to 3 days after the last dialysis treatment. Group C
consisted of 9 apparently healthy nonazotemic men
(ages 26 to 50 years; average age 37 years).
Preparation of serum (Fig. 1). All serum samples
were filtered at 4° C through a UM- 10 filter (Amicon
Co., Lexington, Massachusetts) under nitrogen
pressure at 20 kg/cm2 while they were being washed
with Dulbecco' s phosphate-buffered saline (PBS)
(Grand Island Biological Co., Grand Island, New
York). This filtration increased the volume of fil-
trate five to eight times. These UM-lO filtrates were
then passed through UM-05 filters under the same
conditions, which reduced the volume to one half the
original. The fluids retained in the second filtration,
hereafter called "retentates," were tested in trip-
licate on the cultured marrow described below.
UM- 10 retentates are proteinaceous fluid containing
immunoglobulins and potential heteroantibodies in-
hibitory to the rabbit marrow regardless of whether
they came from patients with uremia or normal
people, and were not studied further. UM-05 fil-
trates showed no toxicity in preliminary studies.
Most of the UM-05 retentates from groups A and B
were chromatographed on Sephadex® G-15 col-
umns (Pharmacia Inc., Piscataway, New Jersey)
monitored by UV spectroscopy at 206 nm with a
Uvicord Ill® (LKB, Inc., Bromma, Sweden). The
gel filtration was done with Sephadex G-15 in a
manner similar to that of FUrst, Zimmerman, and
Bergstrom [16], by using a 0.6X70-cm Cheminert
column (Milton Roy Co., Riviera Beach, Florida).
Serum 4° C
UM-lO filtration and
washing with PBS
Filtrate Retentate
Concentrated to one
half original volume
UM-OS filter
Filtrate Retentate used
in these studies
Fig. 1. Preparation of serum.
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All columns were developed with PBS at 18 mi/hr at
4° C (pH, 7.2). Sephadex G-15 gel was chosen origi-
nally because of the studies carried out by FUrst et
al. This gel, when used in a narrow column, ap-
peared to give a better resolution of separation.
These columns were calibrated with insulin (M 210,
Eli Lilly Co., Indianapolis, Indiana), penta-L-ala-
nine (p-3884, Sigma Co., St. Louis, Missouri), an-
giotensin II (Hyperstat, CIBA, Summitt, New Jer-
sey), arginine vasopressin (0-4250, Sigma), nico-
tinamide adenine dinucleotide NADPH (reduced
form, N-0505, Sigma), creatinine (Sigma), uric acid
(Sigma), vitamin B12 (Invenex, Grand Island, New
York), and urea (Schwartz/Mann, Orangeburg,
New Jersey). Sephadex G-50 chromatography was
also done in three of the same serum samples. The
inhibitory material was present in the early peak as
it was with the G-15 separation, but recovery was
more difficult. Therefore, the majority of the studies
have been carried out with the G-15 Cheminert col-
umn. Filtrate appearing before the first absorbance
peak was used as an internal "column control"
when measuring the effect of various eluates on
bone marrow DNA synthesis. These fractions were
tested without further concentration, dilution, or
dialysis. Bacteriologic monitoring of the Sephadex
columns was periodically carried out. If appreciable
growth (50 colonies/mi) were detected, the gels
were decontaminated by first washing the column
with 0.02% sodium azide and then washing thor-
oughly with PBS before serum filtration. All test
samples were passed through a Millipore® 0.45-s
membrane before they were added to the culture
systems.
Additional studies to characterize the inhibitor(s)
required a larger amount of serum. Consequently,
plasmapheresis (approved by the Human Studies
Committee) was done in 1 of the 14 group B pa-
tients. Approximately 1.5 liters of plasma were re-
moved in six runs in volumes of 250 to 300 ml each
time from patient 22. An additional 4 liters of
plasma were collected during a clinically indicated
plasmapheresis from patient 6.' These serum sam-
ples were stored in aliquots at —20° C and pro-
cessed as described above, but the retentates were
concentrated 10-fold to 20-fold. These concentrated
retentates were used for the characterization stud-
ies described below.
This patient was discovered to have antiglomerular basement
membrane glomerulonephritis 1 month after the onset of uremia.
Plasmapheresis did not improve his uremic state.
Culture systems. For the tritiated thymidine and
ferrous 59 incorporation studies, we used bone mar-
row of young male New Zealand rabbits, each
weighing 1.3 to 2.3 kg. The rabbit femoral marrow
was collected and dispersed by agitation in Eagle's
minimal essential media (EMEM) with Hanks salts
(Gibco, New York) and passing through small-
guage needles. The cells were resuspended with
20% Plasmagel® (Roger Bellon Laboratories,
Neuilly, France), added to settle the erythrocytes.
The nucleated cells were removed, and approxi-
mately 5 x 106 cells were resuspended per milliliter
of culture media containing penicillin (200 U/mi)
and streptomycin (50 g/ml). Of the cell suspen-
sion, 200 l were pipetted into each well of a Linbro
plate (FB-l6-24-TC, Linbro, Inc., New Haven,
Connecticut). One hundred microliters of each test
substance or PBS or "column control" were then
added to the cell suspension in triplicate. In-
cubation was carried out at 36° C, with 5% carbon
dioxide, 20% oxygen, and 100% humidity. After 30
mi erythropoietin (Step III, Connaught Inc., Wil-
lowdale, Ontario) in 20-l volumes was added to all
wells except a set of three controls. Three hours lat-
er, 2 tCi of tritiated thymidine in l0 M unlabeled
thymidine in a volume of 100 l of autologous rabbit
serum was added. The final incubation mixture is
listed in Table 1. Seventeen to twenty hours later,
the cultures were harvested to count the radio-
activity.
For the ferrous 59 incorporation studies, we used
a modification of the method of Fink and Fisher
[17]. Briefly, the marrow was dispersed in a mixture
of 80% NCTC 109 (Microbiological Associates, Be-
thesda, Maryland) and 20% heat-inactivated (56° C
for 30 mm) fetal calf serum (Gibco) containing pen-
icillin, streptomycin, and sodium heparin (10 U/mi).
The cells were processed as described above except
that the Plasmagel step was omitted and the count
was adjusted to 106/ml. Just before addition of 450
pA of cells and culture media, 5 pA of rabbit serum
containing 1.2 tCi of ferrous 59 (specific activity, 13
mCilg ferric citrate; New England Nuclear, Bos-
ton, Massachusetts), 0.05 U of erythropoietin, and
50 j.tl of test substance were added to each well. The
amount of protein-free test fluid in this system is
smaller than it is in the thymidine incorporation
studies. The test fluid contained no measurable
iron. Forty-five hours of incubation were carried
out under the same conditions as described above.
The cultured cells were harvested for measure-
ment of thymidine incorporation by adding 1 N so-
dium hydroxide to the entire contents of the well to
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Table 1. In vitro culture system in thymidine incorporation studies
Sequence
of addition Substance
Volume
p1
Final
concentration
I Marrow cells in minimal essential medium 140 1.0 X 106 cells/mI
2 Fetal calf serum 60 15% v/v
3 Test substance 100 24% v/v
4 Erythropoietin 20 0.4 U/nil
5 3H-thymidine in autologous rabbit serum 100 4.5 1.sCi/2.2 X 10 mmoles/ml
Total volume/well 420
lyse the cells. The lysate (100 pJ) was placed on
Whatman #3 paper discs (3M Co., Mirneapolis,
Minnesota), after which they were washed with 5%
trichloroacetic acid and 95% ethanol [18]. Some of
the plates were harvested by an automated harves-
ter (Otto Hiller Co.. Madison, Wisconsin). The pa-
per discs containing the newly synthesized DNA
macromolecules were dried, placed in toluene-Per-
mablend (Packard, Downers Grove, Illinois), and
counted in a liquid scintillation counter. For mea-
surement of ferrous 59 incorporation into heme, we
used a modified Goldwasser technique [19]. The
cells were washed twice in hypertonic saline, lysed
with Tris potassium chloride-magnesium and 1%
NP 40 (Nonidet P40, Shell Chemicals). The lysate
was extracted into cyclohexanone (Eastman Kodak
Co., Rochester, New York) and counted in a gam-
ma counter. Statistical evaluation of these results
was done by Student's t test for unpaired groups,
and evaluation of the following studies was done by
analysis of variance with the modification designed
by Dunnett [20].
Characterization studies. We collected larger
amounts of serum from 2 clinically stable patients
on maintenance dialysis. After preparing a 10- or
20-fold concentrated retentate chromatographed on
a G-15 column, we collected aliquots of the first-
peak material, and we performed the following ad-
ditional studies on the aliquots showing inhibitory
activity.
(a) The effect of temperature was tested by heat-
ing to 56° C for up to 1 hr and to 100° C for 5 mm.
(b) The effect of proteolytic enzymes was exam-
ined by incubation with commercially available cel-
lulose-bound enzymes for 30 mm at 37° C, after
which the enzyme-cellulose complex was removed
by centrifugation. The enzymes used in these stud-
ies were protease (P-0387, Sigma), papain (P-8011,
Sigma), and chymotrypsin (C-7260, Sigma) fixed to
carboxymethyl cellulose (CMC). Their specific ac-
tivities are shown in Fig. 7. For controls, we tested
the active material after incubation with CMC with-
out the bound enzymes. We also tested the effect of
enzyme-cellulose complex on saline solutions to
rule out the introduction of nonspecific con-
taminating inhibitory material.
(c) The solubility of the active substance from
chloroform was determined by testing the aqueous
phase before and after volume-for-volume extrac-
tion of 5 ml of the active material with triple-dis-
tilled reagent-grade chloroform. Extractions were
done three times at room temperature. The extracts
in the chloroform fraction were tested after the
chloroform was evaporated under a nitrogen stream
and the material was resuspended in 1 ml of PBS.
PBS controls were extracted and tested in an identi-
cal manner.
(d) The protein content of representative sam-
ples of active material was determined by the fluo-
rosamine method [21].
(e) Several nitrogenous substances known to be
present in uremic sera, whose physical character-
istics are such that they would be expected to be
found in the UM-lO filtrates, were tested in the mar-
row culture system. We tested a mixture of reagent
grade creatinine (20 mg/dl), urea (300 mg/dl),
methylguanidine (5 mg/dl), and guanidosuccinic
acid (5 mg/dl). In addition, we tested the effect of
exogenous PTH using two sources of material: (1)
synthetic 1—34 (courtesy of Dr. David Onjes of the
University of North Carolina) and (2) bovine (lot
601304, 570 U/mg, Calbiochem, San Diego, Califor-
nia). Doses of 0.1, 1.0, 10, and 100 ng/ml of each
were added in triplicate.
Results
Effect of retentate on tritiated thymidine incorpo-
ration. Table 2 summarizes the results of studies in
which we surveyed the effect of the UM-05 reten-
tates prepared after initial filtration of serum
through a UM-lO filter. Almost all retentates were
studied on two occasions; and in all studies, values
shown were the average of triplicate determina-
tions. The variations were within 8% of the mean in
95% of the cases. The percent inhibition from the
individual study of each serum was given separately
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Table 2. Percent inhibition of marrow 3H-tritiated thymidine uptake by UM-05 retentates from three groups of subjectsa
Uremic patients
Nonazotemic subjects
Group C
Pt no.
Group A
(Before first
dialysis)
Avg
Group B
(After starting
maintenance dialysis)
Pt no. Avg Pt no. Avg
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Gr
(23,27)
(34,40)
(17, 12)
(22,37)
(29,20)
(23)
(12, 15)
(0,9)
(0, 18)
(16,10)
(12, 16)
(6,9)
(16,20)
(15,6)
oupmeans
25
37
15
30
25
23
14
5
9
13
14
8
18
11
18
1(1, —3)
2(9,9)
3 (13, 22)
4 (—2,6)
5 (14,23)
6 (13)
15 (0, —1)
16 (—5, —12)
17 (3, 8)
18 (—1,7)
19 (14,3)
20 (9, 15)
21(12, 17)
22 (10, 12)
—2
9
18
2
19
13
—1
—9
6
3
9
12
15
11
8
23
24
25
26
27
28
29
30
31
(9,9)
(—15,1)
(—9, —4)
(0,3)
(—9,0)
(5,2)
(0, —10)
(1, —6)
(—6, —7)
9
—7
—7
4
—5
4
—5
—3
—6
—2
a Numbers in parentheses indicate separate values determined, in triplicate, on different marrow preparations. Group A > group B, P
<0.005. Group A > group C, P < 0.001. Group B > group C, P < 0.005.
(control) — cpm (experimental)b Percent inhibition was calculated from I — X 100.
cpm (control)
in parentheses, and the average percent inhibition
for each specimen was recorded. Finally, the group-
average percent inhibition was calculated. Samples
from undialyzed uremic patients (group A) inhibited
tritiated thymidine incorporation significantly more
than did those patients on maintenance dialysis
(group B). Patients 1 through 6 were in both groups
A and B, and their sera caused significantly less in-
hibition after the start of maintenance dialysis than
they did before (P < 0.05). Retentates from non-
azotemic men caused no inhibition, and the mean
value was significantly less than it was in the other
two groups. No correlation between the anemia and
the in vitro inhibition of cultured marrow was
noted.
Effect of retentate on ferrous 59 incorporation.
Serum UM-05 retentates from 7 uremic patients
(group A) caused a 35 7% (sr't) reduction of fer-
rous 59 incorporation into heme. The retentates of 6
maintenance dialysis patients (group B) caused less
inhibition (26 12%). Those from 8 nonazotemic
patients (group C), conversely, demonstrated 15
5% enhancement. The difference between groups A
and B was not statistically significant due to the
wide variation. Groups A and B, respectively, dif-
fered significantly from group C (P < 0.00 1 and P <
0.01).
Chromatography of retentates from group A and
B patients. Sephadex G-50 gel chromatography of a
retentate prepared from a patient with uremia re-
vealed three broad peaks of UV absorption. Sam-
ples of each of these peaks were tested in the cul-
tured marrow system with both tritiated thymidine
and ferrous 59 as markers. In this study (Fig. 2), the
material from the first absorbance peak inhibited
the specific uptake of thymidine and iron. There
was no measurable iron in any of the chromato-
graphed peaks because the initial UM-lO filtration
of serum substantially excluded the proteins car-
rying iron. Sephadex G-15 chromatography (Fig. 3)
of the same retentate appeared to provide a narrow-
er band of first-peak material. In this and other iden-
tical studies, the first well-resolved peak that ap-
peared just after the beginning of elution reproduc-
ibly inhibited tritiated thymidine incorporation
whereas little or no inhibition was seen in later frac-
tions.
Retentates of 10 of the 14 group A (uremic) and 13
of the 14 group B (dialysis) patients and patient 10,
whose retentate had not been tested after he had
begun maintenance dialysis, were chromatographed
on a G-15 Sephadex column, and the first-peak ma-
terial was studied in the marrow culture system.
Most samples were studied on two or more occa-
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Fig. 2. UM-05 retenrate (1 ml) from the serum of a group A (ure-
mic) patient chromato graphed on a Pharmacia Sephadex G-50
column. Three UV absorbance peaks (.___.)were observed.
The abscissa represents the volume of elution. These and other
fractions from the column were tested in the rabbit marrow cul-
ture system with both tritiated thymidine (open bars) and ferrous
59 (hatched bars) as markers. The uptake of either marker by the
marrow incubated with aliquots form the first absorbance peak,
probably containing substance of mol wt well over 1000 daltons,
was significantly (P < 0.01) less than that of saline control or of
other peaks.
x
E
a)
0
E
>.
sions; and in all cases, the values were the average
of triplicate determinations with reproducibility
similar to the survey of their retentates. Table 3
shows the average degree of inhibition of tritiated
thymidine incorporation caused by the first peaks
prepared from the inhibitory retentates. First peaks
; of both groups caused inhibition, and those from
: group A caused significantly greater inhibition.
There was a significant correlation between the de-
gree of inhibition caused by retentates and corre-
sponding first peaks (Fig. 4). Serial dilutions of the
first-peak material from patients 6 and 22 were also
tested in the tritiated thymidine bone marrow sys-
tem. A dose-response relationship was noted (Fig. 5).
Effect of heat on inhibitor. First-peak material
from 2 of the group B patients (6 and 22) was stud-
ied before and after it was heated to 56° C and
100° C (Fig. 6). Heating to 100° C for 5 mm com-
pletely removed the inhibitory activity. There was,
however, no significant change of inhibitory activity
after heating to 56° C for 60 mm.
Effect of proteolytic enzymes on inhibitor. Con-
centrated retentates (X 10) from 2 of the group B pa-
tients (6 and 22) were prepared from large volumes
of serum and tested after exposure to cellulose-
bound proteolytic enzymes. Nonspecific effects
were tested by exposing the samples to cellulose
without bound enzymes. In both cases, there was
loss of the first-peak inhibitory activity after ex-
Table 3. Percent inhibition of marrow tritiated thymidine uptake
by G-15 Sephadex first peaks from two groups of uremic
patients"
Group A
(Before
first dialysis)
Group B
(After starting
maintenance dialysis)
Ptno. AvgPtno. Avg
1 (22,24)'
2 (21, 27, 42)
3 (19, 10)
4 (25,23,23,29)
5 (19, 16)
6 (10)
7 (15, 23)
8 (30, 19)
9 (33)
14 (26,20)
Groupmeans
23
30
15
26
18
10
19
25
33
23
22
2
3
4
5
6
8
10
15
17
18
20
21
22
(—5,—4,—3) —4
(20, 17, 10) 16
(23, 19) 21
(11) 11
(19, 14) 17
(26, 28) 27
(23, 24) 22
(8, 12) 10
(1, 6, 12) 7
(0) 0
(12, 8, 10) 10
(—3) —3
(3) 3
(18, 28) 23
11
Numbers in parenthesis indicate separate values determined,
in triplicate, on different marrow preparations. Group B <group
A, P < 0.005.
First peakI
A0 206
C-,
J
Fig. 3. The same retentate (1 ml) used for Fig. 1 chromato-
graphed on a Sephadex G-15 Cheminert column. The inhibition
is almost wholly confined to the first absorbance peak when com-
pared with other fractions (P < 0.01). Vertical bars (I) represent
the means and ranges.
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effect on the marrow. By the fluorosamine method
for peptide determination [21], both fractions (Table
4), as well as the interphase material (data not
shown), showed detectable peptides.
Effect of PTH and other nitrogenous substances
on cultured marrow. PTH from bovine or synthetic
sources have no effect at concentrations of up to 10
ng'ml. At 100 ng/ml, the synthetic substances
caused slight inhibition of tritiated thymidine up-
take (Fig. 8). A solution containing creatinine (20
mg/dl), urea (200 mgldl), methylguanidine (5 mg/dl),
and guanidosuccinic acid (5 mg/dl) was not inhib-
itory.
Discussion
0 10 20 30 40
% Inhibition with retentate
Fig. 4. Activities of retentates (abscissa) and fractionated ref en-
fates (peaks I) (ordinate) shown graphically. The inhibitory ma-
terial present in the retentate correlated with that in the first
peak.
posure to papain and protease, and the effect
showed dose responsiveness. Figure 7 shows the ef-
fects of increasing the doses of each of the three
enzymes on the inhibitory material from patient 22
in comparison to comparable amounts of the carrier
cellulose.
Chloroform solubility. Inhibitory activity of first-
peak material from patients 6 and 22 was measured
before and after chloroform extraction (Table 4).
The inhibitory activity was substantially reduced in
the aqueous fraction with the appearance of some
activity in the organic fraction. Saline controls be-
fore or after the same procedure did not show any
The present data indicate that the sera of pa-
tients with uremia contain a factor or a group of fac-
tors that inhibit DNA synthesis in cultured marrow.
Maintenance dialysis is associated with a reduction
of the inhibition. The inhibitory activity resides
largely in a serum fraction having a mol wt less than
10,000 daltons and probably greater than 1000 dal-
tons. The inhibitor(s) is stable at 56° C but is com-
pletely inactivated by brief heating to 100° C, is sen-
sitive to proteolytic enzymes, and is partially sol-
uble in chloroform.
The results of these and other studies [6—14] re-
quire some qualifications. It is to be cautioned that
the inhibition of DNA synthesis in cultured marrow
is an in vitro phenomenon. Similarly, previous re-
ported studies showing the effect of uremic serum
on cultured marrow should be viewed in like man-
ner [9, 11, 12]. Neither they nor we have found any
quantitative relation between the degree of inhibi-
tion of in vitro marrow activity caused by uremic
serum and the severity of anemia in these patients.
Second, although maintenance dialysis is associat-
ed with a reduction in the activity (or amount) of in
vitro inhibition, it is possible that the reduction is
not directly the consequence of the dialytic process.
For example, improved electrolyte status and nutri-
tion may lead to reduced production of such sub-
stances. Neither do our data provide direct and con-
clusive evidence that the inhibitory activity comes
from a single or multiple species of substance. Our
data and the study model, however, do provide a
useful in vitro method for the detection and charac-
terization of some toxic uremic substances. As far
as we know, only one study of uremic patients and
their blood has purported to show a quantitative rela-
tionship between a clinical problem (neurotoxicity)
and an in vitro observation (inhibition of a frog sural
nerve function) [22]. Chemical characterization of
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Fig. 6. Effects of heat on inhibitory activity. The inhibitory effect (ordinate) of first-peak material from 2 patients was not reduced by
heating to 56° C for 60 mm. After only 5 mm at 1000 C (see inset), inhibitory effect was completely abolished (P < 0.001).
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the active material in their study suggests the pres-
ence of an acidic poiyoi with a carbohydrate struc-
ture [23] but not polypeptide(s) as others have pre-
viously postulated [16, 24-27] and as we have dem-
onstrated with enzyme digestion.
The in vitro test we have chosen is a short-term
culture of rabbit marrow in which incorporation of
tritiated thymidine into macromolecular DNA is
measured. There are several reasons for this
choice: (1) previous studies have shown that in vitro
proliferation of bone marrow elements, usually
erythrocyte precursors, is inhibited by uremic sera
[6, 9-15]; (2) bone marrow cells can be evenly sus-
pended for large scale studies to test numerous sam-
ples; (3) harvesting of these samples is rapid, repro-
ducible, and not nearly as laborious as heme extrac-
tions or counting of cell colonies [15, 19]; and(4) the
specific activity of thymidine, identical in all cul-
Table 4. Inhibitory activity and peptide content of whole and partitioned first peak
Patient
Before extraction
Chloroform extraction
Aqueous phase Organic phase
% Peptide% Peptide % Peptide
no. Study Inhibition pg/mi Inhibition p.g/ml Inhibition pg/mi
6 1 31 23 17
2 24 13 12
Mean 28 16 18 8.2 15 2.1
22 3 37 13 26
4 29 15 9
5 42 31 18
6 36 31 28
Mean 36 21 23 15 20 2.8
722 Gutman and Huang
50
40
C
. 30
.0
.0C
20
10
560 C
L
0
C0
.0
.0C
0 0.14 0.38 0.56 U papain
0 0.08 0.16 0.32 U protease
0 0.15 0.30 0.60 U chymotrypsin
0 0.50 1.0 2.0 mg carboxymethycellulose
Fig. 7. First-peak material from patients 22 and 6 exposed to
cellulose-bound proteolytic enzymes in increasing amounts fr 3
hr at 37° C. There was a graded reduction of inhibition effect
caused by protease and papain (P < 0.001). Enzyme-free cellu-
lose in a concentration greater than 2 mg per incubation reduced
the inhibition presumably due to entrapment or adherence of the
inhibitor. The same results (not shown) were noted with the first
peak from patient 6.
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Fig. 8. The effect of bovine and synthetic PTH on the incorpora-
tion of tritiated thymidine by marrow cells.
tures, is unaffected by very small amounts of thymi-
dine in the cell.
The principal concerns associated with the use of
this system are: (I) the variability of baseline tn-
tiated thymidine incorporation from one animal to
another; (2) the ever present possibility of non-
specific inhibitory contaminants being introduced
into this biologic system; and (3) the lack of speci-
ficity of cell type(s) being inhibited. Our expression
of inhibition as a fraction of the uptake in the pres-
ence of saline or "column" controls minimizes the
seriousness of the first problem. With regard to the
problem of nonspecific inhibition, precautions were
taken with each study. Saline and "column" con-
trols were tested repeatedly in each study. In the
early evaluation of this culture system, we had en-
countered inhibition associated with microbial con-
tamination and with the filtration through other fil-
ters. These potential problems were carefully ruled
out. We acknowledge that inhibition of tritiated
thymidine incorporation is not specific for any
single marrow cell type. The observation, however,
that both tritiated thymidine uptake into DNA and
ferrous 59 incorporation into heme are reduced sug-
gests that erythrocyte precursors share in the inhi-
bition of DNA synthesis.
Our report provides partial characterization of
the inhibitory substance(s) by exposing the active
fractions to heat, proteolytic enzymes, and organic
solvent extraction. Most other studies have report-
ed chemical analysis of the active fractions on the
assumption that the majority of the organic material
present in the fraction was responsible for the bio-
logic effect (see page 230 of Ref. 2). The active frac-
tions we have found are stable at 56° C, but heating
to 1000 C for 5 mm results in complete loss of activi-
ty. Our present data also indicate significant sensi-
tivity of the inhibitor(s) to two different proteolytic
enzymes, thus providing evidence that the active
components of the inhibitor(s) are peptides.
These observations are compatible with the pos-
sibility that the toxic components in the uremic sera
detectable by this assay are in the mol-wt range of
1000 to 10,000 daltons, which may be peptides par-
tially bound to lipids or peptides consisting of most-
ly nonpolar amino acids. The uremic substances
with inhibitory properties found and partially char-
acterized by others are also likely polypeptides [16,
24-27]. But, the bone marrow inhibitors found by
Wallner and Vautrin in the blood of patients with
uremia were completely soluble in chloroform and
insoluble in ether [14]. Possibly the conditions un-
der which they did the extraction from whole serum
rather than from the low-molecular-weight fraction
of serum may have increased the organic solubility
of the same material we have detected. Conversely,
if the substance(s) detected in their assay is entirely
lipid as they suggest, it would be bound to protein
and would not pass the UM-lO membrane. Thus,
their substance(s) would be different from ours.
Studies of peptides and proteolipids are an advanc-
ing field of biochemistry. With better understanding
and availability of new methodology afforded in the
future, the final characterization and isolation of the
toxic uremic substance(s) may become possible.
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